ClinConnect ClinConnect Logo
Search / Trial NCT06741956

Development of a Wearable Device for Osteoporosis Prevention and Fracture Risk Reduction in Women

Launched by UNIVERSITY OF SEVILLE · Dec 15, 2024

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

Osteoporosis Prevention Postmenopausal Women Bone Mineral Density Fragility Fractures Physical Activity Interventions Wearable Technology Non Pharmacological Management Machine Learning In Healthcare

ClinConnect Summary

CURRENT STATUS AND JUSTIFICATION OF THE PROPOSAL Osteoporosis is an important public health problem and it is characterized by the deterioration of the microarchitecture of bone tissue and a low bone mineral density (BMD) that leads to a reduction in bone strength and the consequent increased risk of skeletal fractures 1. One in three women will suffer an osteoporotic fracture in their lifetime 2. In fact, it is estimated that more than 200 million people suffer from osteoporosis and these figures are increasing due to the aging of the population and the change in lifestyles 3. A recent sys...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Postmenopausal women older than 40 years with ≤ 10 years after menopause ("early postmenopausal women").
  • Sedentary women (defined as not performing regular physical activity greater than 150 min of moderate-vigorous physical activity per week in the last six months).
  • Willing to give consent to participate in the study.
  • Exclusion Criteria:
  • Surgically induced menopause or cancer treatment.
  • Low BMI (\<18 kg / m2).
  • Excessive alcohol consumption (≥3 drinks per day).
  • Smoker
  • Unstable cardiovascular disease.
  • Rheumatoid arthritis.
  • Chronic kidney disease
  • Diagnosis of conditions that alter bone metabolism (hypo/hypercalcemia, hyperthyroidism, hypo/hypergonadism).
  • Upper or lower limb fracture in the last 6 months.
  • Mobility problems or requiring assistance to walk.
  • Participation in physical exercise programs in the 6 months prior to the study.
  • Regular use of glucocorticoids or hormone replacement therapy in the past 3 months.
  • Unwillingness to complete the study requirements.

About University Of Seville

The University of Seville is a prestigious academic institution dedicated to advancing knowledge through innovative research and exceptional education. With a strong emphasis on interdisciplinary collaboration, the university actively engages in clinical trials aimed at enhancing patient care and medical outcomes. Its commitment to rigorous scientific inquiry and ethical standards positions it as a leading sponsor in the field of clinical research, fostering partnerships with healthcare professionals and institutions to drive advancements in medical science and improve public health.

Locations

Seville, , Spain

Patients applied

0 patients applied

Trial Officials

Borja Sañudo, PhD

Principal Investigator

University of Seville

Sergio Tejero, PhD

Principal Investigator

Hospitales Universitarios Virgen del Rocío

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported